跳至主要内容
临床试验/NCT00041509
NCT00041509已完成2 期

ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty

GlaxoSmithKline0 个研究点目标入组 343 人开始时间: 2002年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
343
主要终点
VTE

研究概览

简要总结

The purpose of this study is to gain additional safety information as well as to determine after the study drug has been given to patients who have undergone total hip replacement surgery, whether the study drug is effective in preventing late deep vein thrombosis (blood clots in legs) or pulmonary embolism (blood clots in lungs).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients scheduled for primary elective unilateral total hip arthroplasty (i.e. first time the hip is being replaced on the operative side).
  • Patients who have given written informed consent to participate in this study.

排除标准

  • Patients with a contraindication to contrast venography
  • Patients with an increased risk of bleeding.
  • Patients with a predefined risk for prethrombotic episodes or a history of thrombophilia.
  • Other inclusion or exclusion criteria to be determined by the physician and study sponsor.

研究组 & 干预措施

SB424323, 500 mg BID

Experimental

干预措施: SB-424323 (Drug)

SB424323, 125 mg BID

Experimental

干预措施: SB-424323 (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

VTE

时间窗: 28 day treatment period

Incidence of VTE during the 28-day treatment period, including death due to VTE

次要结局

  • types of VTE(28 day treatment period)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

ThromboEmbolism Prevention Efficacy and Safety Trial... | 临床试验